{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Allogeneic+Stem-Cell+Transplant",
    "query": {
      "condition": "Allogeneic Stem-Cell Transplant"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1024,
    "total_pages": 103,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Allogeneic+Stem-Cell+Transplant&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T23:42:42.952Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04530487",
      "title": "Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Desmoplastic Small Round Cell Tumor",
        "Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Desmoplastic Small Round Cell Tumor",
        "Recurrent Malignant Peripheral Nerve Sheath Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Recurrent Rhabdomyosarcoma",
        "Refractory Desmoplastic Small Round Cell Tumor",
        "Refractory Malignant Peripheral Nerve Sheath Tumor",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Rhabdomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Lapine T-Lymphocyte Immune Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 1,
      "start_date": "2020-08-19",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2025-06-29",
      "last_synced_at": "2026-07-23T23:42:42.952Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04530487"
    },
    {
      "nct_id": "NCT00609609",
      "title": "Photopheresis for the Treatment of Acute Graft Versus Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Versus Host Disease"
      ],
      "interventions": [
        {
          "name": "Photopheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 81,
      "start_date": "2008-01",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2018-06-04",
      "last_synced_at": "2026-07-23T23:42:42.952Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00609609"
    },
    {
      "nct_id": "NCT02210065",
      "title": "Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2015-03-03",
      "completion_date": "2019-05-13",
      "has_results": true,
      "last_update_posted_date": "2020-03-17",
      "last_synced_at": "2026-07-23T23:42:42.952Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02210065"
    },
    {
      "nct_id": "NCT00034528",
      "title": "Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemoglobinopathies",
        "Anemia, Sickle Cell",
        "Hemoglobin SC Disease",
        "Thalassemia",
        "Thalassemia Major"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "FK506",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2001-09",
      "completion_date": "2003-11",
      "has_results": false,
      "last_update_posted_date": "2013-05-01",
      "last_synced_at": "2026-07-23T23:42:42.952Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00034528"
    },
    {
      "nct_id": "NCT02477878",
      "title": "Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Lymphoma",
        "Multiple Myeloma",
        "Hematologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "BPX-501",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bellicum Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-07",
      "completion_date": "2033-01",
      "has_results": false,
      "last_update_posted_date": "2022-07-12",
      "last_synced_at": "2026-07-23T23:42:42.952Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Westwood, Kansas • Buffalo, New York + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02477878"
    },
    {
      "nct_id": "NCT01611298",
      "title": "Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myelogenous Leukemia",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndrome",
        "Hodgkin Lymphoma",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tetanus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Robert Krance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "3 Years to 70 Years"
      },
      "enrollment_count": 7,
      "start_date": "2008-03",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2020-04-21",
      "last_synced_at": "2026-07-23T23:42:42.952Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01611298"
    },
    {
      "nct_id": "NCT01629511",
      "title": "Allogeneic Stem Cell Transplant for CLL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplantation Recipient",
        "Chronic Lymphocytic Leukemia",
        "Prolymphocytic Leukemia",
        "Richter Syndrome"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2012-11-21",
      "completion_date": "2018-04-25",
      "has_results": true,
      "last_update_posted_date": "2020-02-24",
      "last_synced_at": "2026-07-23T23:42:42.952Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01629511"
    },
    {
      "nct_id": "NCT05179057",
      "title": "Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adenovirus Infection"
      ],
      "interventions": [
        {
          "name": "Posoleucel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AlloVir",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 57,
      "start_date": "2022-04-26",
      "completion_date": "2024-01-31",
      "has_results": true,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-07-23T23:42:42.952Z",
      "location_count": 23,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 19 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05179057"
    },
    {
      "nct_id": "NCT02458235",
      "title": "Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphoid Leukemia",
        "Juvenile Myelomonocytic Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "azacitidine",
          "type": "DRUG"
        },
        {
          "name": "donor lymphocyte infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "Up to 29 Years"
      },
      "enrollment_count": 17,
      "start_date": "2015-06-02",
      "completion_date": "2019-03-15",
      "has_results": true,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-07-23T23:42:42.952Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02458235"
    },
    {
      "nct_id": "NCT03147742",
      "title": "An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Graft-versus-host Disease (GVHD)"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2022-06-07",
      "last_synced_at": "2026-07-23T23:42:42.952Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03147742"
    }
  ]
}